Loxo Oncology Inc (LOXO) : Dafna Capital Management scooped up 28,256 additional shares in Loxo Oncology Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 130,222 shares of Loxo Oncology Inc which is valued at $3,794,669.Loxo Oncology Inc makes up approximately 3.40% of Dafna Capital Management’s portfolio.
Other Hedge Funds, Including , Price T Rowe Associates Inc Md added LOXO to its portfolio by purchasing 33,163 company shares during the most recent quarter which is valued at $966,370. California State Teachers Retirement System sold out all of its stake in LOXO during the most recent quarter. The investment firm sold 27,964 shares of LOXO which is valued $635,901.Teacher Retirement System Of Texas boosted its stake in LOXO in the latest quarter, The investment management firm added 33,451 additional shares and now holds a total of 34,933 shares of Loxo Oncology Inc which is valued at $690,625. Loxo Oncology Inc makes up approx 0.01% of Teacher Retirement System Of Texas’s portfolio.Ubs Asset Management Americas Inc boosted its stake in LOXO in the latest quarter, The investment management firm added 21,477 additional shares and now holds a total of 230,575 shares of Loxo Oncology Inc which is valued at $4,558,468. Loxo Oncology Inc makes up approx 0.01% of Ubs Asset Management Americas Inc’s portfolio.
Loxo Oncology Inc opened for trading at $27.7 and hit $28.41 on the upside on Monday, eventually ending the session at $28.13, with a gain of 1.30% or 0.36 points. The heightened volatility saw the trading volume jump to 81,033 shares. Company has a market cap of $610 M.
Loxo Oncology Inc. is engaged in discovery development and commercialization of targeted cancer therapies. LOXO-101 is the Company’s lead product and has completed its pre-clinical research. LOXO-101 is an oral selective inhibitor of the tropomyosin receptor kinase (TRK) family. The Company is developing it for the treatment of tumors with TRK alterations. TRK has been implicated in various tumor types such as lung cancer head and neck cancer melanoma colorectal cancer sarcoma and breast cancer. The Company is conducting Phase 1 clinical trial of LOXO-101 which is an open label multicenter trial and has two stages: dose escalation and expansion. The objectives of the dose escalation stage are to determine the tolerated dose and the appropriate dose for further clinical investigation as well as to determine the tolerability and pharmacokinetic profile of orally administered LOXO-101.